Why Codexis Shares Are Slumping Today
Codexis Inc (NASDAQ:CDXS) expects Q2 sales of approximately $38 million and FY22 sales of 135 million to $141 million, below the…
UnitedHealth Q2 Earnings Surpass Street View Led By Growth In Both Segments, Lifts FY22 Earnings Outlook
UnitedHealth Group Inc (NYSE:UNH) has reported Q2 FY22 sales of $80.3 billion, up 13% Y/Y, beating the consensus of $79.68…
NexImmune Shares Soar Following FDA’s Clearance To Initial-Stage HPV Cancer Study
NexImmune, Inc. (NASDAQ: NEXI) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for its first cellular therapy product candidate NEXI-003 addressing solid tumors.
Lawmaker Warns San Francisco Faces ‘Public Health Mess’ Over Monkeypox Vaccine Shortage
A California state legislator representing the Bay Area declared San Francisco is "veering toward a public health mess" after the city’s Department of Public Health acknowledged it is running out of monkeypox vaccine and will have to shutter one of its clinics until the supply is replenished.
Omega Therapeutics Gets FDA Nod For Initial-Stage Liver Cancer Study
The U.S. Food and Drug Administration (FDA) has announced clearance to Omega Therapeutics’ (NASDAQ: OMGA) Investigational New Drug (IND) to initiate a Phase 1/2 clinical study of its candidate OTX-2002 for the treatment of hepatocellular carcinoma (HCC).
Beigene’s Inspections Delay Suggest Eventual Approval, Says This Analyst
Beigene Limited (NASDAQ: BGNE) provided a regulatory update on the anticipated US approval decision for the Biological License Application for tislelizumab in 2L metastatic esophageal squamous cell carcinoma (ESCC).
SVB Likes This ‘Novel Antipsychotic’-Focused Stock
SVB Leerink initiated coverage on Karuna Therapeutics Inc (NASDAQ:KRTX) with an Outperform rating and a price target of $170. SVB notes that…
Moderna’s COVID-19 Vaccine Scores Canadian Approval For Kids Below 5 Years
Health Canada has approved the use of Moderna Inc’s (NASDAQ:MRNA) mRNA COVID-19 vaccine, Spikevax, in a two-dose series of 25 µg…
Why Novavax Shares Are Plunging Today Despite Much Awaited FDA Emergency Nod?
The European Medicines Agency identified severe allergic reactions as potential side effects of Novavax Inc’s (NASDAQ:NVAX) COVID-19 vaccine. A few cases of…
Summit Therapeutics Mulls Additional Trial For Its Once Failed Infection Candidate
Summit Therapeutics Inc (NASDAQ:SMMT) provided an update on the clinical development of ridinilazole, its lead Phase 3 product candidate for Clostridioides…